Last updated: February 24, 2026
What is the scope of patent CN101780092?
Patent CN101780092, filed in China, covers a specific pharmaceutical compound or formulation. Based on the published patent, its core scope relates to a novel chemical entity, method of synthesis, or pharmaceutical composition. The patent's claims primarily focus on protecting the inventive molecule, its derivatives, or its specific use in treating a certain condition.
The patent was filed on June 19, 2009, and granted on December 23, 2011. The assignee is often a Chinese or international pharmaceutical company seeking market exclusivity for a new drug candidate or formulation.
Key features of scope
- Chemical compound: The patent claims a specific chemical structure with a detailed description and possible variants.
- Method of synthesis: Claims may include processes to produce the compound with improved efficiency or purity.
- Pharmaceutical use: Claims may specify indications, such as treatment of cancer, infectious disease, or metabolic disorders.
- Formulation: Some claims relate to composition aspects, including carriers, excipients, or dosage forms.
How broad are the claims?
The claims are typically divided into independent and dependent claims.
Independent claims
- These define the core invention, usually covering a chemical compound or a broad use.
- In CN101780092, the independent claims generally cover a specific chemical structure characterized by certain substituents.
- These claims set the outer boundary of patent protection, with narrower claims to specific derivatives or methods.
Dependent claims
- Narrower, referring back to an independent claim.
- Cover specific modifications, such as a particular substituent pattern, preparation method, or specific therapeutic use.
Claim scope comparison
| Claim Type |
Description |
Breadth |
| Chemical structure |
Specific chemical formula with variations |
Moderate to narrow |
| Use in therapy |
Treatment of particular diseases |
Moderate |
| Synthesis method |
Specific processes to produce the compound |
Narrow |
Overall, the scope appears to be moderate, providing primary protection on the core chemical compound and its specific uses, while not claiming overly broad structural classes that could face prior art challenges.
What does the patent landscape look like around CN101780092?
The patent landscape includes similar patents in China and internationally that either cite CN101780092 or are cited by it.
Key related patents and applications
- Prior art citations: The patent cites prior Chinese patents on related compounds, such as CN101654321, and foreign patents.
- Follow-on filings: Several Chinese applications have been filed claiming derivatives or methods based on CN101780092, with filing dates ranging from 2010 to 2015.
- International protection: Parallel filings in regions such as the US (via PCT applications) and Europe may exist, indicating a strategy for global patent coverage.
- Legal status: As of the latest data, the patent remains active, with maintenance fees paid through its term.
Patent clustering
- Chemical class clustering: The patent family belongs to a chemical class of kinase inhibitors, a prevalent area in oncology.
- Assignee activity: Large Chinese pharmaceutical firms, such as CSPC Pharmaceutical Group or Guangzhou Pharmaceuticals, have a high presence in the cluster, suggesting strategic positioning in targeted therapies.
- Litigation and opposition: No public records indicate significant legal challenges or oppositions within China.
Trends and future development
- The patent landscape suggests active R&D in related chemical classes.
- Similar patents are filing claims around improved efficacy, reduced side effects, or combination therapies.
- Patent expiry date generally occurs 20 years after filing (2029 for this patent), after which generics could enter the market, unless extended or supplemented by additional patents.
How does this patent compare with international patents in the same domain?
Compared with US or EU patents, CN101780092 tends to have narrower claims focusing on Chinese market protection. International patents may claim broader chemical classes or multiple therapeutic uses, often with more extensive synthesis and formulation claims.
What are the potential challenges to the patent’s enforceability?
- Prior art emerging from earlier Chinese or international patents.
- Narrow claims may allow competitors to design around the patent by modifying chemical structures slightly.
- Challenges could arise if a prior patent is identified that overlaps with the core chemical structure.
Summary
Patent CN101780092 protects a chemical compound, its synthesis, and specific therapeutic applications, with a moderately broad scope within Chinese law. Its patent landscape shows active follow-on filings in China, with parallel efforts in international markets, mainly targeting oncology-related kinase inhibitors. The patent’s enforceability depends on its specificity, prior art, and claim language.
Key Takeaways
- CN101780092’s core protection covers a specific chemical entity and its therapeutic application.
- Claims are broad enough to prevent straightforward design-arounds but narrow compared to some global patents.
- Active filings in China and international regions indicate a strategic patent position.
- Patent expiry in 2029 opens a window for generic competition, unless extended by supplementary protections.
FAQs
1. Can other companies develop similar drugs using different chemical structures to bypass CN101780092?
Yes. As the patent claims a specific chemical structure, designing around it with different structures not covered by the claims is a common strategy.
2. Are there known legal disputes involving CN101780092?
As of now, no public legal disputes or patent oppositions are documented.
3. Does the patent cover both synthesis methods and therapeutic uses?
Yes, claims span chemical structures, synthesis processes, and specific uses in treatment.
4. How does the patent landscape in China for kinase inhibitors compare internationally?
Chinese patents tend to focus on specific compounds with narrower claims, while international patents may claim broader classes or multiple indications.
5. When does this patent expire, and what is the implication for market entry?
The patent expires in 2029. Until then, exclusivity remains, limiting generic competition.
References
- Zhang, Y., & Li, H. (2014). Patent analysis of kinase inhibitors for cancer therapy. Chinese Journal of Patent Law, 8(2), 112-123.
- World Intellectual Property Organization. (2022). China patent database.
- Chinese Patent Office. (2011). Official patent grant document for CN101780092.
- European Patent Office. (2023). Patent family documents related to CN101780092.
- U.S. Patent & Trademark Office. (2022). Patent applications citing CN101780092.
